Fostemsavir

Research use only, not for human use.

BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.

Fostemsavir, also known as BMS-663068, is a oral, safe and effective HIV-1 attachment inhibitor. BMS-663068 is a prodrug of the small-molecule inhibitor BMS-626529, which inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells.(In Vivo):Fostemsavir (BMS-663068) has good antiviral activity in subjects infected with virus shown to be susceptible (IC50, <100 nM) to the agent.

——

Fostemsavir (BMS-663068) has good antiviral activity in subjects infected with virus shown to be susceptible (IC50, <100 nM) to the agent.

BMS-663068 | BMS 663068 | Fostemsavir

Angiogenesis

Adrenergic Receptor

HIV-1

Infection

——

864953-29-7

583.5

C25H26N7O8P

>98% (HPLC)

DMSO : ≥ 100 mg/mL 171.38 mM H2O : 20 mg/mL 34.28 mM

COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12

(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl dihydrogen phosphate

(-20℃)

With Ice Pack

≥ 2 years